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Abstract
Purpose The Pictorial Representation of Illness and Self
Measure-Revised 2 (PRISM-R2) has been developed as
generic measure to assess suffering. The aim of this study
was to evaluate the ability of this instrument to identify
long-term cancer survivors with high levels of suffering
who may need additional support.
Methods 1299 cancer survivors completed the PRISM-
R2, the Short Form Health Survey (SF-36), and the Quality
of Life-Cancer Survivors questionnaire (QoL-CS). The
PRISM-R2 distinguishes between the Self-Illness Separa-
tion (SIS) and Illness Perception Measure (IPM), both
measuring aspects of suffering.
Results 112 (9%) cancer survivors reported high suffer-
ing according to IPM. This group had a higher cancer stage
at diagnosis, more cancer recurrences, more comorbidities,
and were lower educated compared to people reporting less
suffering. The PRISM-R2 could explain substantial
amounts of variance (10–14%) in the psychological aspects
of the SF-36 and QoL-CS. The IPM also discriminated
statistically and clinically signiﬁcant between high- and
low-health status.
Conclusion The PRISM-R2 proved to be able to dis-
criminate between individuals with good and deteriorated
levels of QoL. Further evaluation of its validity and
screening potential is recommended.
Keywords Oncology  Survivors  PRISM-R2 
Suffering  Quality of life
Abbreviations
ANOVA Analyses of variance
BP Bodily pain
ECR Eindhoven Cancer Registry
GH General health
IPM Illness Perception Measure
MH Mental health
MCS Mental component summary
PCS Physical component summary
PRISM Pictorial Representation of Illness and Self
Measure
PRISM-R2 Pictorial Representation of Illness and Self
Measure-Revised 2
PF Physical functioning
QoL Quality of Life
QoL-CS Quality of Life-Cancer Survivors
questionnaire
RE Role emotional functioning
RP Role physical functioning
SIS Self-Illness Separation
SF-36 Short Form Health Survey
SF Social functioning
VT Vitality
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AccordingtoCassell,sufferingisevokedby‘‘theimmediate
onslaughtofdistress-physical,emotional,orsocial’’andthat
the main objective of medicine is to alleviate suffering [1].
Hefurtheremphasizesthattheintactnessofapersonneedsto
be threatened and that ‘‘the interpretation of events deter-
mines whether suffering or merely distress is experienced’’
[1]. In this sense, suffering can be seen as a qualitatively
different and more severe state of physical, emotional, or
social distress. Based on these conceptualizations, the
authors suggest that (especially in the long run) the
(re)interpretations, explanations, and understanding of what
has happened are essential for cancer survivors to come to
terms with their former disease and to place it/accept it in
their lives. Research has shown that some people surviving
cancer report fear of recurrences and/or long-term compli-
cations, restrictions in daily (social) life, working life, and
sexual functioning resulting in deteriorated levels of quality
oflife(QoL)andincreaseddistress[2,3].Dependingonhow
these (and other) aspects dominate or arise in a cancer sur-
vivor’s life, a state of suffering could be developed.
The Pictorial Representation of Illness and Self Mea-
sure-Revised 2 (PRISM-R2) is a modiﬁed version of the
original Pictorial Representation of Illness and Self Mea-
sure (PRISM) [4] which can be used to assess the extent to
which people suffer from an (somatic) illness. As of now
the PRISM and PRISM-R2 have been exclusively admin-
istered and evaluated in patients with current diseases or
symptoms [4–16]. This study wants to take a step further
and examines to what extent cancer survivors still suffer
from the aftermath of their disease. The authors aim to
bring together suffering with the construct of QoL and it
was assumed that those who suffer more, may be more
likely in need of additional support and care.
This study sets out two foci: the investigation of the sur-
vivorsandtheinstrument.First,theauthorsexamineifandto
what extent, cancer survivors are still affected by their for-
mer disease and treatment. Second, it was to evaluate the
properties of the PRISM-R2 by examining its associations
with QoL and health status as well as testing its possible
screening capacity. The authors expect the PRISM-R2 to be
an efﬁcient, quick, and easy-to-use tool for both health care
provider andpatientbecauseoftheimplicitstrongstatement
that can be made by the patient with this visual task.
Method
Design and recruitment
This is a secondary analysis of a population-based, cross-
sectional survey on long-term survivors of prostate
cancer, endometrial cancer, Hodgkin’s, and non-Hodg-
kin’s lymphoma that was conducted at the Eindhoven
Cancer Registry (ECR) in 2004. The ECR collects data
from all patients newly diagnosed with cancer in the
southern part of the Netherlands, which is an area that has
2.3 million inhabitants. The ECR was used to select all
patients who were diagnosed with endometrial or prostate
cancer between 1994 and 1998 and patients who were
diagnosed with Hodgkin’s and non-Hodgkin’s lymphoma
between 1989 and 1998. Participants older than 75 years
at diagnosis were excluded because it was expected that
they would have difﬁculties completing the measures
without assistance. To exclude all patients who had died
before November 2004, the database was linked with the
database of the Central Bureau for Genealogy, which
collects Dutch mortality statistics through the civil
municipal registries. After excluding all deceased patients,
data collection was started in November 2004. Medical
specialists sent their (former) patients a letter to inform
them about the study, together with the questionnaires.
The letter explained that, by returning the completed
questionnaires, the patient agreed to participate and con-
sented to linkage of the questionnaire data with their
disease history as registered in the ECR. Patients were
reassured that non-participation would not have any
consequences for their follow-up care or treatment.
Approval for this study was obtained from a local certi-
ﬁed Medical Ethics Committee.
Measures
PRISM-R2
The original PRISM [4] examines the degree of suffering
by using a visual task performance. It consists of a disk
(labeled as ‘‘self’’) placed in the lower right corner of a
white A4-sheet which is labeled as one’s living environ-
ment. Patients are requested to place a so-called illness-
disk (labeled ‘‘my medical problem’’) in relation to their
self-disk and living environment. Since the developers of
the PRISM-R2 [10] felt that the self should be in the centre
of one’s life, they modiﬁed it into a circle with the self-disk
in its centre. In addition, they included three different sizes
of the illness-disk (smaller, equal to, and bigger than the
self-disk). Picture 1a and b both illustrate the design and
possible applications of the PRISM-R2. Two outcome
variables, both tapping aspects of suffering, are obtained
with this instrument. First, the distance from the centre
of the self to the centre of the illness-disk represents the
Self-Illness Separation (SIS), ranging from 0 to 93 mm.
Following Pincus and Morley [17], a separation between
illness and self schema is assumed to signify a healthy
adjustment to the illness. The PRISM, assessing the
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123subjective position of one’s illness in relation to the self,
seems to match this deﬁnition rather well [11]. Second, the
chosen illness disk size stands for the so-called Illness
Perception Measure (IPM) which represents the perceived
severity of the former disease. Therefore, a smaller disk
(lower IPM) corresponds to lower levels of perceived
severity of the aftermath of cancer. The participants
received a written instruction to choose the illness-disk
which represented the perceived impact of their former
cancer on their current life best, and put it in relation to
themselves and their environment. In this study, a paper-
version of the PRISM-R2 was used and the illness-disks
were provided as stickers to allow completion of all mea-
sures in the home situation and returning the package by
mail.
SF-36
The 36-Item Short Form Health Survey (SF-36) [18]
measures health status on eight subscales: physical func-
tioning (PF), role physical functioning (RP), bodily pain
(BP), general health (GH), vitality (VT), social functioning
(SF), role emotional functioning (RE), and mental health
(MH). The scores of these scales are converted into a
0–100 scale with higher scores indicating a better func-
tioning. Furthermore, the eight scales can be summed up
into two domains: the physical component summary (PCS)
and mental component summary (MCS).
QoL-CS
The Quality of Life-Cancer Survivors questionnaire (QoL-
CS) assesses QoL in connection to cancer survivorship
[19]. It is a 44-item visual analog scale, based on a scale
from 0 (worst outcome) to 10 (best outcome). The items
can be transformed into four scales: physical, psychologi-
cal, social, and spiritual well-being. Furthermore, a total
score can be calculated incorporating all four scales and
displaying an estimate of the overall QoL. The QoL-CS
examines issues of particular concern to cancer survivors,
such as distress since diagnosis, sexuality, employment,
uncertainty about the future, and the role of spirituality and
religion. The QoL-CS has been demonstrated to be a reli-
able and valid instrument [19–22], although the subscale
spiritual well-being showed low reliability in the Dutch
population [19]. The same pattern has been found in this
sample: a low Cronbach’s alpha for spiritual well-being
(.49) while the other subscales and the total score showed
satisfying to high-internal consistencies ranging from .71
(social), .86 (physical), .88 (psychological), to .90 (total
score).
Statistical analyses
All statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS, version 17.0 Chicago,
IL, USA). Socio-demographic and clinical data were tested
for differences between the respondents and non-respon-
dents using v
2 analyses for categorical variables and t-tests
for continuous variables. Furthermore, analyses of variance
(ANOVA) and v
2 tests were used (respectively for SIS and
IPM) to examine differences on the PRISM-R2 related to
socio-demographicor clinical data suchas: age atdiagnosis,
time since diagnosis, gender, marital status, socio-eco-
nomical status (SES), education, cancer stage at diagnosis,
primary treatment, comorbidity, cancer recurrence, and the
use of counseling. SES has been rated using the guidelines
of the institute Statistics Netherlands which has developed
an indicator of SES for each postal code (on average, 17
Picture 1 a Illustration of PRISM with adequate coping and
integration (small illness-disk far away from self). b Illustration of
PRISM with large continued impact of cancer (large illness-disk close
to self)
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123households) based on aggregated individual ﬁscal data
concerning the economic value of the home and household
income. SES was categorized into tertiles: low (decile 1–3),
medium (4–7), or high (8–10) [23]. Comorbidity was
assessed with a slightly adapted version of the Charlson
comorbidity index [24]. For a more adequate interpretation
of the SF-36-results, the scores of the patient sample were
compared with a large, random, nationwide normative
sample of adults (n = 1742) taken from the general Dutch
population [18]. The authors matched this sample with the
sample in terms of age and gender. Given the large amount
ofsimultaneouscomparisons,itwasadjustedthealpha-level
was adjusted using the Bonferroni-method. Subsequently, it
was used Norman’s rule of thumb was used, stating that the
threshold of discrimination for changes in health status
scores for a chronic disease is approximately half a standard
deviation, to assess the magnitude of differences [25].
In order to evaluate the convergent validity of the
PRISM-R2, correlations with the subscales and summary
scores of the SF-36 and QoL-CS were computed. Corre-
lations lower than .3 were considered weak and correla-
tions above .5 strong [26]. Finally, it was tested how much
variance the PRISM-R2 could predict in the health status
and QoL in this sample of long-term cancer survivors
controlling for socio-demographic and clinical data. Socio-
demographic and clinical data included: age, survival time,
gender, marital status, socio economical status, education,
cancer type, stage, amount of comorbid disorders, and
cancer recurrence.
Results
Participants
One thousand four hundred and seventy-ﬁve people
returned complete questionnaires (80%). In comparison to
the respondents, the non-respondents were on average
somewhat older (66 vs. 69 years; t =- 3.189; P = .001).
Both groups did not differ regarding their gender and
survival time. Of the 1475 respondents, 176 people (12%)
did not complete the PRISM-R2 and these patients were on
average older (74 vs. 67 years; t =- 9.996; P\.0001),
more often widowed (24% vs. 12%; v
2 = 23.908;
P\.0001), and more often lower educated (60% vs. 42%;
v
2 = 31.336; P\.0001).
The ﬁnal sample of 1299 participants consisted of long-
term prostate cancer survivors (n = 651; 50%), endome-
trial cancer survivors (n = 265; 20%), and survivors of
non-Hodgkin’s (n = 258; 20%) and Hodgkin’s lymphoma
(n = 125; 10%). Socio-demographic and clinical charac-
teristics of the participants are displayed in Table 1.
PRISM-R2
Within the whole sample, the SIS ranged from 0 to
172 mm (mean: 59.1, SD: 27.8). Twenty-nine participants
placed their illness-disk (against the instructions) outside of
the circle (94–172 mm) labeled as environment. However,
these people did not differ from those that placed the ill-
ness-disk on the boundaries of the circle (n = 457; SIS
range: 76–93 mm) regarding socio-demographic and clin-
ical data.
Socio-demographic and clinical differences associated
with the SIS scores were found in such way that the highest
educated participants reported higher average SIS scores.
Whereas participants who experienced new primary tumors
or relapses obtained signiﬁcantly lower SIS scores.
The majority of the participants (66%) chose the smallest
illness-disk (IPM = 1) to symbolize the perceived impact
of their former cancer disease whereas 112 (9%) chose the
largest disk (IPM = 3). Examining differences on the IPM
yielded results comparable to SIS. Higher educated people
as well as participants who did not have any new tumors or
relapses, chose smaller illness-disks (v
2 = 46.056; P\
.0001 and v
2 = 38.964; P\.0001, respectively). Further-
more, participants with a higher amount of comorbid
disorders, or those previously diagnosed with stage IV
disease, were more likely to choose the large illness-disk
(v
2 = 27.162; P\.0001 and v
2 = 15.307; P = .018,
respectively; see Table 1). Interestingly, people with a
shorter time since diagnosis compared to people with a
longer survival time (median split: 8.3 years) did not differ
on SIS and IPM.
The association between SIS and IPM was found to be
moderate (r =- .33; P\.0001) and indicated that smaller
IPMs were generally associated with larger SISs and vice
versa.
Cancer survivors versus normative population
Cancer survivors, as a whole group, reported statistically
signiﬁcant (P\.001) lower levels of health status, as
measured with the SF-36, compared to the age- and sex-
matched normative population, except for the subscales
social functioning and mental health that failed to reach the
adjusted level of signiﬁcance (P = .005). However, the
differences between cancer patients and the normative
population ranged from 1 to 7 points and were therefore not
considered clinically meaningful [25] (see Table 2).
Subsequently, survivors were divided into three groups
on the basis of IPM and comparisons of these three groups
to the normative population showed a different picture.
Those who chose a large illness-disk (9%) reported sta-
tistically (P\.001) and clinically signiﬁcant lower levels
of scores on all domains of the SF-36. In contrasts,
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123Table 1 Socio-demographic and clinical description for the whole sample and separated by IPM; comparisons of differences in distributions
between the IPM-groups
Small disk
n = 861
Medium disk
n = 326
Large disk
n = 112
F diff. Whole sample
n = 1299
Mean (SD)
Range
Mean (SD)
Range
Mean (SD)
Range
Mean (SD)
Range
Age at diagnosis 57.6 (14.2) 59.4 (12.3) 59.0 (10.2) 58 (13.4)
9–75 7–75 30–75 7–75
Years since diagnosis 8.7 (2.0) 8.6 (1.8) 8.7 (1.6) 9 (1.9)
6–15 6–15 6–14 6–15
n (%) n (%) n (%) v
2 n (%)
Cancer type
Endometrial 179 (20.8) 64 (19.6) 22 (19.6) 265 (20.4)
Hodgkin 97 (11.3) 22 (6.7) 6 (5.4) 125 (9.6)
Non-Hodgkin 173 (20.1) 64 (19.6) 21 (18.8) 258 (19.9)
Prostate 412 (47.9) 176 (54) 63 (56.3) 651 (50.1)
Sex
Female 312 (36.2) 105 (32.2) 33 (29.5) 450 (34.6)
Male 549 (63.8) 221 (67.8) 79 (70.5) 849 (65.4)
Marital status
Single 637 (74) 242 (74.2) 88 (78.6) 967 (74.4)
Married 75 (8.7) 20 (6.1) 5 (4.5) 99 (7.6)
Divorced 37 (4.3) 16 (4.9) 2 (1.8) 55 (4.2)
Widowed 104 (12.1) 43 (13.2) 16 (14.3) 163 (12.4)
Unknown 8 (0.9) 5 (1.5) 1 (0.9) 15 (1.2)
SES
a
Low 177 (20.6) 78 (23.9) 31 (27.7) 286 (22.0)
Medium 354 (41.1) 141 (43.3) 47 (42.0) 542 (41.7)
High 302 (35.1) 99 (30.4) 31 (27.7) 432 (33.3)
Unknown 28 (3.3) 8 (2.4) 3 (2.7) 39 (3.0)
Educational level
Low 310 (36.0) 172 (52.8) 68 (60.7) 46.056** 550 (42.3)
Medium 325 (37.7) 101 (31.0) 27 (24.1) 454 (34.9)
High 209 (24.3) 47 (14.4) 16 (14.3) 272 (20.9)
Unknown 17 (2.0) 6 (1.8) 1 (0.9) –
Stage
I 370 (43.0) 134 (41.1) 33 (29.5) 15.307* 537 (41.3)
II 326 (37.9) 133 (40.8) 48 (42.9) 507 (39.0)
III 56 (6.5) 15 (4.6) 7 (6.3) 78 (6.0)
IV 68 (7.9) 29 (8.9) 19 (17.0) 116 (8.9)
Unknown 41 (4.8) 15 (4.6) 5 (4.5) 61 (4.7)
Primary treatment Surgery
Chemotherapy 388 (45.1) 151 (46.3) 47 (42.0) 586 (45.1)
Radiotherapy 177 (20.6) 61 (18.7) 19 (17.0) 257 (19.8)
Hormonal therapy 170 (19.7) 55 (16.9) 21 (18.8) 246 (19.8)
Wait and see 78 (9.1) 36 (11.0) 17 (15.2) 131 (10.1)
Unknown 42 (4.9) 21 (6.4) 8 (7.1) 71 (5.5)
6 (0.7) 2 (0.6) – 8 (0.6)
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123survivors who chose a small illness-disk reported statisti-
cally signiﬁcant higher levels of health status compared to
the normative population, except for the subscales general
health and vitality, which both failed to reach statistical
signiﬁcance. Again the mean differences were quite small,
suggesting comparable levels of health status between the
Table 1 continued
Small disk
n = 861
Medium disk
n = 326
Large disk
n = 112
F diff. Whole sample
n = 1299
Mean (SD)
Range
Mean (SD)
Range
Mean (SD)
Range
Mean (SD)
Range
Comorbidity
None 267 (31.0) 66 (20.2) 24 (21.4) 27.162** 357 (27.5)
1 315 (36.6) 108 (33.1) 39 (34.8) 463 (35.6)
C2 278 (32.3) 152 (46.6) 49 (43.8) 479 (36.9)
Cancer recurrence 128 (14.9) 77 (23.6) 42 (37.5) 38.964** 247 (19)
Counseling
GP
b 89 (10.3) 44 (13.5) 24 (21.4) 12.290* 157 (12.1)
Physiotherapist 34 (3.9) 22 (6.7) 12 (10.7) 11.154* 68 (5.2)
Psychologist 32 (3.7) 18 (5.5) 8 (7.1) 58 (4.5)
a SES socio economical status
b GP general practitioner
* P\.05; ** P\.0001
Table 2 Mean scores and standard deviations (SD) from the whole sample and stratiﬁed by IPM regarding every psychological measurement
(PRISM-R2, SF-36, and QoL-CS); One-way ANOVA testing group differences
Whole sample
n = 1299
IPM = 1
n = 861 (66%) (1)
IPM = 2
n = 326 (25%) (2)
IPM = 3
n = 112 (9%) (3)
Sign. diff. Norm
a
PRISM-SIS 59.12 (27.8) 0–172 65.7 (27.0) 0–172 47.9 (23.8) 0–140 41.2 (26.8) 0–135 1[2, 3**
SF-36
PF 69.2
 (27.2) 74.5
 (24.9) 60.1
 (28.5) 53.3
 (28.7) 1[2, 3** 72.1
RP 63.6
 (42.6) 73.3
 (38.5) 47.2
 (44.6) 32.9
 (39.8) 1[2[3** 68.8
BP 77.9
 (24.1) 82.6
 (21.3) 70.7 (25.1) 62.8
 (28.9) 1[2[3** 72.3
GH 57.4
 (21.8) 63.4 (19.7) 47.5
 (19.8) 40.0
 (22.3) 1[2[3** 64.6
VT 63.4
 (21.1) 68.4 (19.2) 55.2
 (20.7) 48.7
 (22.6) 1[2[3** 67.0
SF 79.8 (23.4) 85.4
 (19.6) 71.2
 (24.4) 61.7
 (29.9) 1[2[3** 81.5
RE 75.1
 (39.3) 84.1
 (32.5) 60.5
 (44.8) 47.1
 (45.4) 1[2[3** 80.9
MH 75.4 (18.1) 79.3
 (15.7) 70.0
 (18.1) 60.7
 (23.3) 1[2[3** 76.5
PCS 44.3
 (11.2) 46.8
 (10.1) 40.0
 (11.7) 37.3
 (10.9) 1[2[3** 45.4
MCS 51.6
 (9.9) 54.0
 (8.2) 47.9
 (10.8) 43.2
 (12.3) 1[2[3** 52.9
QoL-CS
Physical 7.4 (2.1) 7.9 (1.9) 6.7 (2.2) 6.1 (2.1) 1[2[3**
Psychol.
b 6.5 (1.6) 6.9 (1.4) 5.8 (1.6) 4.9 (1.8) 1[2[3**
Social 6.9 (1.7) 7.3 (1.4) 6.3 (1.8) 5.6 (1.9) 1[2[3**
Spiritual 4.7 (1.5) 4.8 (1.5) 4.6 (1.4) 4.4 (1.5) 1[3*
QoL
c 6.5 (1.3) 6.8 (1.1) 6.0 (1.2) 5.1 (1.4) 1[2[3**
a Norm normative population
b Psychol. psychological
c QoL quality of life total score
 Signiﬁcantly different from normative population (P\.0001), but see text for clinical meaningfulness
* P\.05; ** P\.0001
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123normative population and cancer survivors with a small
IPM. The group that chose a medium illness-disk took an
intermediate position. All subscales (except for bodily
pain) turned out to be signiﬁcantly lower compared to the
normative population, but these were clinically meaningful
on only ﬁve subscales: RP, GH, VT, FF, RE.
After comparing each IPM-group to the normative
group, the authors additionally explored whether the IPM
discriminated within the sample of cancer survivors with
respect to health status and QoL. Signiﬁcant differences
emerged on every subscale of the SF-36 and QoL-CS
where the small illness-disk was always associated with the
highest levels of health status and QoL. The two groups
choosing the medium- and large-IPMs did not always
appear to be signiﬁcantly different from another (i.e., SF-
36-physical functioning and QoL-CS-spiritual well-being;
see Table 2).
Associations of PRISM-R2 with SF-36 and QoL-CS
SIS correlated weakly (r = .12 to .23; P\.0001) with the
subscales of the SF-36 and QoL-CS, while IPM showed
weak to moderate negative associations with these sub-
scales (r =- .10 to -.45; all P\.0001; Table 3). The
highest association was found between IPM and the QoL-
CS-total score (r =- .45; P\.0001; see also Table 3).
See also Fig. 1 for an overview of the results of all self-
report measures stratiﬁed by the chosen illness-disk (IPM).
When predicting the SF-36-MCS and QoL-CS-total
score using multiple linear regressions, a rather small
amount of variance (8 and 17%, respectively) could be
explained in the ﬁrst step using socio-demographic and
clinical data. However, the addition of SIS and IPM in the
second step led to a substantial increase in the explained
Table 3 Correlations of the SIS and IPM with the subscales of the
SF-36 and QoL-CS
Subscale PRISM-SIS PRISM-IPM
PRISM-SIS – -.329
SF-36-PF .142 -.280
SF-36-RP .176 -.334
SF-36-BP .123 -.283
SF-36-GH .227 -.391
SF-36-VT .186 -.335
SF-36-SF .172 -.350
SF-36-RE .198 -.331
SF-36-MH .156 -.331
SF-36-PCS .168 -.312
SF-36-MCS .187 -.363
QoL-CS-physical .166 -.325
QoL-CS-psychological .261 -.412
QoL-CS-social .198 -.362
QoL-CS-spiritual .086 -.088
QoL-CS-total score .263 -.445
All displayed correlations are signiﬁcant at the 1%-level
Fig. 1 Outcome on the
PRISM–SIS, QoL–total score
and the SF36–component
summaries by sicker sizes
[small n=861; medium n=326;
big n=112]
Qual Life Res (2011) 20:1645–1654 1651
123variance up to 20 and 34% (F = 16.121; P\.0001 and
F = 32.025; P\.0001, respectively). The same overall
patterns were found for the SF-36-PCS, but the PRISM-R2
did not add as much value as in more psychologically
related aspects. In this case, socio-demographic and clini-
cal data already explained 25% of the variance and the ﬁnal
model, also including the PRISM-R2 values, explained a
variance of 32% (F = 29.406; P\.0001).
Overall, IPM was by far the most weighted factor pre-
dicting health status and QoL in all of these regression
analyses.
Discussion
Given the two foci on the study, the aims were threefold:
(1) to examine suffering in long-term cancer survivors; (2)
to investigate the properties of the PRISM-R2; and (3) to
obtain a better insight into its possible use as a measure to
identify cancer survivors who may need additional support
and care.
The majority of participants chose a small illness-disk
(66%) and tended to place it quite far away from their self
symbolizing the separation between themselves and their
former cancer diagnosis and treatment. This may be inter-
preted as indicating adequate coping and the integration of
the cancer experience in their current life. On the other
hand, still 9% of long-term (6–15 years after diagnosis)
cancer survivors chose the large illness-disk, which was
associated with distress and suffering. This mainly con-
cerned patients with lower education, cancer recurrence,
more comorbid conditions, and a higher tumor stage at
diagnosis. Lower education indeed might be expected to
have a negative impact on one’s capacity to deal with
diseases like cancer. As already suggested in the literature
[27, 28], higher educated people may have more resources
or coping skills allowing more effective coping with their
former disease. Cancer recurrences, higher comorbidity,
and more severe tumor stages are all very plausibly asso-
ciated with more suffering. It should be noted that
comorbid conditions may occur independent of the cancer
and treatment itself, but are nevertheless experienced as
additionally burdensome and challenging one’s coping
resources which might result in higher levels of suffering.
Interestingly, time since diagnosis did not have an impact
on the chosen IPM and SIS, suggesting that a longer time
since diagnosis is not necessarily associated with less
suffering.
A limited number of participants (n = 29) also chose to
place their illness-disk outside of their environment which
was not statistically meaningful, but the authors feel that
the opportunity to do so gave the participants optimal
freedom to visualize their experienced level of suffering.
A serious drawback of most QoL measures is that they
never cover all aspects of the disease that patients consider
as relevant for one’s well-being. In case of the PRISM-R2,
however, the lack of such a predetermined list of aspects
may be regarded as a major asset, because the patient has
optimal freedom to make an internal calculation of all pros
and cons, each with his or her personal weight factor. In
that way, this measure may be considered a more qualita-
tive screening measure that overcomes some of the most
serious difﬁculties of QoL measures [29].
The obtained pattern of correlations of the PRISM-R2
with the SF-36 and QoL-CS met the expectations and also
corroborated previous ﬁndings [10]. Of major signiﬁcance
is the ﬁnding that IPM and SIS were both stronger asso-
ciated with subscales assessing psychological and social
well-being, rather than physical health, which is in line
with Cassell’s conceptualizations of suffering as a pre-
dominantly psychological construct.
Cancer survivors with small illness-disks (low IPM)
proved to be comparable to the normative population with
respect to health status, while participants who chose a
large illness-disk (high IPM) reported signiﬁcantly lower
levels of health status. This result was supported by the
regression analyses which consistently showed IPM to be
by far the most important factor predicting health status
and QoL. Small Illness-disks were always associated with
higher levels of health status and QoL compared to the
normative population, suggesting that they are not likely to
be characterized by severely deteriorated levels of well-
being. On the other hand, patients choosing a medium or
large illness-disk are more likely in need of attention in
clinical practice. Overall, the discriminative ability of the
IPM supports the notion of a good speciﬁcity of the
PRISM-R2 by producing right-negative results. Small ill-
ness-disks indicate low levels of suffering and need no or
little clinical attention while medium and especially large
illness-disks should raise concern since they can be inter-
preted as indicating extra need for attention and support.
Nonetheless, it is crucial to also take the SIS into account
in order to obtain a more complete impression of the degree
of suffering.
This study was the ﬁrst to examine the properties of the
PRISM-R2 in a cohort not currently suffering from a
severe disease and suggests provisional support of its
validity and screening ability which should encourage
further evaluation. Nevertheless, one major limitation
needs to be addressed: lower educated people appeared to
have more problems to complete the PRISM-R2 task,
indicating that a certain cognitive capacity is needed to
understand this more abstract measure. This also suggests a
limited applicability for the generic use of the PRISM-R2.
However, in a clinical setting (different from the study
presented here), patients can be better instructed and have
1652 Qual Life Res (2011) 20:1645–1654
123the opportunity to ask questions about the task and
completion could be facilitated also for low educated
individuals.
The PRISM, like most screening tools, should always be
followed by a closer and more thorough examination of the
patient as the information gained from this screening tool
will not provide adequate understanding of the actual needs
of the survivor to identify what actions might be taken to
eliminate/alleviate their self-perceived suffering.
Future research is needed to obtain insight into the
cognitive processes and considerations that result in the
decision why to select a speciﬁc illness-disk and where to
place it, in order to examine this instrument’s construct
validity. More in depth investigations are needed that
investigate the associations between suffering and coping,
denial, distraction, and other defense mechanisms, because
low suffering does not necessarily imply anything about
the way a person has dealt with a life-threatening disease.
Conclusion
The PRISM-R2 might be a valuable addition to the cur-
rently available tools to evaluate suffering and well-being,
and to identify patients with additional need for care and
support, because of the following four aspects: (1) it gives
patients optimal freedom to consider any personally
important aspect when assessing suffering; (2) it facilitates
communication between patients and health care providers;
(3) it has the capacity to stimulate patients to uncover
hidden problems; and ﬁnally (4) it may be useful to eval-
uate all kinds of interventions. In the present cohort of
cancer survivors, 66% were identiﬁed as not suffering
based on the PRISM-R2 variables, in particular IPM. This
group was characterized by similar levels of health status
and QoL compared to an age- and sex-matched normative
population. The authors are aware that the PRISM-R2 is a
rather qualitative measure that cannot yield or withstand
any hard criteria concerning psychometric properties with
the cross-sectional data. However, the authors are conﬁdent
that this study is the ﬁrst (successful) attempt to get more
insight into the usefulness of the PRISM-R2 for cancer
survivors by relating it to QoL and health status measures.
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